{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:51:32Z","timestamp":1790254292224,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"publisher","award":["2016YFC1304901"],"award-info":[{"award-number":["2016YFC1304901"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bone.2019.115121","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T11:46:20Z","timestamp":1572781580000},"page":"115121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis"],"prefix":"10.1016","volume":"130","author":[{"given":"Fang","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-0543","authenticated-orcid":false,"given":"Xiaoling","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leili","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bone.2019.115121_bib0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","article-title":"Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis","volume":"94","year":"1993","journal-title":"Am. J. Med."},{"issue":"10169","key":"10.1016\/j.bone.2019.115121_bib0010","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bone.2019.115121_bib0015","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bone.2019.115121_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2019.115121_bib0025","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40265-019-01072-6","article-title":"Romosozumab: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"issue":"10 Suppl","key":"10.1016\/j.bone.2019.115121_bib0030","first-page":"69","article-title":"Cardiovascular disease and osteoporosis","volume":"28","author":"Baldini","year":"2005","journal-title":"J. Endocrinol. Invest."},{"issue":"11","key":"10.1016\/j.bone.2019.115121_bib0035","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1359\/JBMR.050711","article-title":"Relationship between osteoporosis and cardiovascular disease in postmenopausal women","volume":"20","author":"Tank\u00f3","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2019.115121_bib0040","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrrheum.2012.120","article-title":"Osteoporosis--a risk factor for cardiovascular disease?","volume":"8","author":"Lampropoulos","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bone.2019.115121_bib0045","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-019-05031-5","article-title":"Bone mass density and bone metabolism marker are associated with progression of carotid and cardiac calcified plaque in Chinese elderly population","author":"Liu","year":"2019","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2019.115121_bib0050","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2796.2006.01640.x","article-title":"Prospective Epidemiological Risk Factors Study Group. Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip","volume":"259","author":"Bagger","year":"2006","journal-title":"J. Intern. Med."},{"issue":"6","key":"10.1016\/j.bone.2019.115121_bib0055","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1586\/14779072.4.6.801","article-title":"The osteoprotegerin\/RANK\/RANKL system: a bone key to vascular disease","volume":"4","author":"Kiechl","year":"2006","journal-title":"Expert Rev. Cardiovasc. Ther."},{"issue":"5","key":"10.1016\/j.bone.2019.115121_bib0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000445","article-title":"Wnt signaling in cardiovascular disease: opportunities and challenges","volume":"28","author":"Gay","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"issue":"4","key":"10.1016\/j.bone.2019.115121_bib0065","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1210\/er.2015-1114","article-title":"Inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned","volume":"38","author":"Drake","year":"2017","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2019.115121_bib0070","series-title":"American Society for Bone and Mineral Research Annual Meeting","article-title":"The Long-term odanacatib fracture trial (LOFT): cardiovascular safety results","author":"O\u2019Donoghue","year":"2016"},{"issue":"5","key":"10.1016\/j.bone.2019.115121_bib0075","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1210\/jc.2018-02236","article-title":"Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials","volume":"104","author":"Lyu","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.bone.2019.115121_bib0080","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1055\/s-0029-1224109","article-title":"Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis","volume":"41","author":"Anastasilakis","year":"2009","journal-title":"Horm. Metab. Res."},{"issue":"4","key":"10.1016\/j.bone.2019.115121_bib0085","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1742-1241.2011.02806.x","article-title":"Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis","volume":"66","author":"Lin","year":"2012","journal-title":"Int. J. Clin. Pract."},{"issue":"1","key":"10.1016\/j.bone.2019.115121_bib0090","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13018-018-0865-3","article-title":"Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis","volume":"13","author":"Wu","year":"2018","journal-title":"J. Orthop. Surg. Res."},{"issue":"2","key":"10.1016\/j.bone.2019.115121_bib0095","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/13697137.2018.1433655","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials","volume":"21","author":"Liu","year":"2018","journal-title":"Climacteric"},{"key":"10.1016\/j.bone.2019.115121_bib0100","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.bone.2019.115121_bib0105","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2019.115121_bib0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2019.115121_bib0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2019.115121_bib0120","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","article-title":"DAPS Investigators. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate","volume":"22","author":"Kendler","year":"2011","journal-title":"Osteoporos. Int."},{"issue":"9","key":"10.1016\/j.bone.2019.115121_bib0125","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bone.2019.115121_bib0130","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00198-011-1786-8","article-title":"Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis","volume":"23","author":"Nakamura","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2019.115121_bib0135","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.bone.2019.115121_bib0140","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"issue":"9886","key":"10.1016\/j.bone.2019.115121_bib0145","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bone.2019.115121_bib0150","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bone.2019.115121_bib0155","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2019.115121_bib0160","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.bone.2019.115121_bib0165","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2019.115121_bib0170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","article-title":"Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study","volume":"103","author":"Ishibashi","year":"2017","journal-title":"Bone"},{"issue":"10102","key":"10.1016\/j.bone.2019.115121_bib0175","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.bone.2019.115121_bib0180","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bone.2019.115121_bib0185","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"18","key":"10.1016\/j.bone.2019.115121_bib0190","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/01.CIR.0000127957.43874.BB","article-title":"Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease","volume":"109","author":"Kiechl","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bone.2019.115121_bib0195","first-page":"631","article-title":"Association of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures and mortality in elderly women","volume":"86","author":"Browner","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bone.2019.115121_bib0200","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/CIRCULATIONAHA.107.707380","article-title":"Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(\u2212\/\u2212) mice","volume":"117","author":"Morony","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bone.2019.115121_bib0205","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jbmr.2043","article-title":"RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk","volume":"29","author":"Samelson","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2019.115121_bib0210","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.bone.2019.115121_bib0215","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jbmr.3019","article-title":"Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study","volume":"32","author":"Choi","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2019.115121_bib0220","doi-asserted-by":"crossref","first-page":"e0122646","DOI":"10.1371\/journal.pone.0122646","article-title":"Bisphosphonates and risk of cardiovascular events: a meta-analysis","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2019.115121_bib0225","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","article-title":"Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis","volume":"252","author":"Kranenburg","year":"2016","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.bone.2019.115121_bib0230","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2019.115121_bib0235","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrendo.2017.136","article-title":"Bone diseases: romosozumab - on track or derailed?","volume":"13","author":"Khosla","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"issue":"15","key":"10.1016\/j.bone.2019.115121_bib0240","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMe1711298","article-title":"Romosozumab - promising or practice changing?","volume":"377","author":"Rosen","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2019.115121_bib0245","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/ATVBAHA.116.308723","article-title":"Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II\u2013induced aortic aneurysm and atherosclerosis","volume":"37","author":"Krishna","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219304144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219304144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:44:51Z","timestamp":1757612691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219304144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":49,"alternative-id":["S8756328219304144"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.115121","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736848931.793584760","asserted-by":"object"}]},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.115121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115121"}}